search
Back to results

A Nasal Applicator for the Treatment of Trigeminal Neuralgia

Primary Purpose

Trigeminal Neuralgia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Nasal ganglion block for TN
Sponsored by
Chicago Anesthesia Pain Specialists
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Trigeminal Neuralgia

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18- 80 years old
  • Trigeminal Neuralgia

Exclusion Criteria:

  • Nasal septal deformity such as: cleft lip and palate, choanal atresia
  • Septal perforation
  • Recent nasal/midface trauma (< 3 months)
  • Bleeding disorder such as Von Willebrand's disease or hemophilia
  • Severe respiratory distress
  • Neoplasm such as the following: Angiofibroma, sinus Tumors, Granuloma
  • Congestion has been present more than 10 days, fever (define as temperature≥ 100.4 F)
  • Current cocaine user
  • Skin around and inside the nasal passage is dry, cracked, oozing, or bleeding
  • Allergy to marcaine
  • Pregnancy

Sites / Locations

  • Chicago Anesthesia Pain Specialists

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Nasal ganglion block for TN

Arm Description

Sphenopalatine ganglion block using the Tx360™ device

Outcomes

Primary Outcome Measures

Pain intensity numeric rating scale
Change in pain intensity before procedure, baseline. And after procedure 15 minutes, 30 minutes, day 1, 7, 14, 21, and 28.

Secondary Outcome Measures

Patient's global impression of change
Before procedure, baseline. And after procedure 30 minutes, day 1, 7, 14, 21, and 28.

Full Information

First Posted
January 2, 2013
Last Updated
September 13, 2017
Sponsor
Chicago Anesthesia Pain Specialists
search

1. Study Identification

Unique Protocol Identification Number
NCT01761604
Brief Title
A Nasal Applicator for the Treatment of Trigeminal Neuralgia
Official Title
The Use of Tx360™ Nasal Applicator for Sphenopalatine Ganglion Block in the Treatment of Trigeminal Neuralgia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chicago Anesthesia Pain Specialists

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The pain from Trigeminal Neuralgia (TN) imposes a substantial burden on patients in daily function and reduces quality of life. The sphenopalatine ganglion, located in the posterior part of the middle nasal turbinate, is involved in the pain associated to TN, by blocking the sphenopalatine ganglion relieves patients from the symptoms. However, methods currently in use to accomplish this are either cumbersome for the patient or invasive regarding the puncture of structures. The purpose of this study is to evaluate the efficacy of Tx360™, a new nasal applicator device, in the treatment of TN. A local anesthetic will be delivered on the ganglion area. We are expecting that this new device will provide at least the same pain relief as the previously described approaches. However, this nasal applicator is intended to be an easy and non invasive method for office use.
Detailed Description
The pain from Trigeminal Neuralgia (TN) imposes a substantial burden on patients in daily function and reduces quality of life. Pain severity correlates with reduced measures of daily functioning, and overall health status. The sphenopalatine ganglion, located in the posterior part of the middle nasal turbinate, is involved in the pain associated to TN, by blocking the sphenopalatine ganglion relieves patients from the symptoms. However, methods currently in use to accomplish this are either cumbersome for the patient or invasive regarding the puncture of structures. The purpose of this study is to evaluate the efficacy of Tx360™, a new nasal applicator device, in the treatment of TN. The Tx360™ is a single use nasal applicator that can reach the sphenopalatine ganglion area. It is designed to dispense medications through a flexible canula. The patients with TN will receive a 0.5 mL spray of local anesthetic on the ganglion area, and measure the change in pain intensity and quality of life. We are expecting that this new device will provide at least the same pain relief as the previously described approaches. However, this nasal applicator is intended to be an easy and non invasive method for office use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trigeminal Neuralgia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nasal ganglion block for TN
Arm Type
Other
Arm Description
Sphenopalatine ganglion block using the Tx360™ device
Intervention Type
Device
Intervention Name(s)
Nasal ganglion block for TN
Primary Outcome Measure Information:
Title
Pain intensity numeric rating scale
Description
Change in pain intensity before procedure, baseline. And after procedure 15 minutes, 30 minutes, day 1, 7, 14, 21, and 28.
Time Frame
Before procedure and after procedure
Secondary Outcome Measure Information:
Title
Patient's global impression of change
Description
Before procedure, baseline. And after procedure 30 minutes, day 1, 7, 14, 21, and 28.
Time Frame
After procedure
Other Pre-specified Outcome Measures:
Title
Modified Brief Pain inventory (short form)
Description
Before procedure, baseline. And after procedure day 1, 7, 14, 21, and 28.
Time Frame
Before procedure and after procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18- 80 years old Trigeminal Neuralgia Exclusion Criteria: Nasal septal deformity such as: cleft lip and palate, choanal atresia Septal perforation Recent nasal/midface trauma (< 3 months) Bleeding disorder such as Von Willebrand's disease or hemophilia Severe respiratory distress Neoplasm such as the following: Angiofibroma, sinus Tumors, Granuloma Congestion has been present more than 10 days, fever (define as temperature≥ 100.4 F) Current cocaine user Skin around and inside the nasal passage is dry, cracked, oozing, or bleeding Allergy to marcaine Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth D Candido, M.D.
Organizational Affiliation
Chicago Anesthesia Pain Specialists
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chicago Anesthesia Pain Specialists
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60657
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Nasal Applicator for the Treatment of Trigeminal Neuralgia

We'll reach out to this number within 24 hrs